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Abstract 
 
CLN6, spanning the endoplasmic reticulum transmembrane, is a protein of unknown 
function.  Mutations in the CLN6 gene are linked to an autosomal recessively inherited 
disorder termed CLN6 disease, classified as a form of the neuronal ceroid 
lipofuscinoses (NCL).  The pathogenesis of CLN6 disease remains poorly understood 
due to a lack of information about physiological roles CLN6 plays.  We previously 
demonstrated that CLN6 has the ability to prevent protein aggregate formation, and thus 
hypothesized that the abrogation of CLN6’s anti-aggregate activity underlies the 
development of CLN6 disease.  To test this hypothesis, we narrowed down the region 
vital for CLN6’s anti-aggregate activity, and subsequently investigated if pathogenic 
mutations within the region attenuate CLN6’s anti-aggregate activity toward four 
aggregation-prone B-crystallin ( BC) mutants.  None of the four BC mutants was 
prevented from aggregating by the Arg106ProfsX truncated CLN6 mutant, the human 
counterpart of the nclf mutant identified in a naturally occurring mouse model of late 
infantile-onset CLN6 disease.  In contrast, the Arg149Cys and the Arg149His CLN6 
mutants, both associated with adult-onset CLN6 disease, blocked aggregation of two out 
of and all of the four BC mutants, respectively, indicating that CLN6’s anti-aggregate 
activity is differentially modulated according to the substitution pattern at the same 
amino acid position.  Collectively, we here propose that the graded reduction in 






CLN6 is an endoplasmic reticulum transmembrane protein, and mutations in the CLN6 
gene are responsible for the development of CLN6 disease, a form of NCL [1–8].  
NCL are a group of hereditary neurodegenerative disorders, characterized by shared 
clinical manifestations such as psychomotor deterioration, epileptic seizures, 
progressive visual impairment, ataxia, and reduced lifespan.  Histologically, 
intralysosomal accumulation of autofluorescent ceroid lipopigments is commonly found 
in patients with NCL.  NCL are heterogeneous in the disease onset and clinical course.  
CLN6 disease is indeed subdivided into late infantile- and adult-onset subtypes [9,10].  
Coupled with a lack of information about physiological roles of CLN6, the pathogenesis 
of CLN6 disease has been largely unknown.  We previously revealed that CLN6 
blocks aggregate formation mediated by a pathogenic BC mutant [11].  This finding 
led us to hypothesize that dysfunction of CLN6 causes a buildup of protein aggregates, 
leading to the development of CLN6 disease.  In fact, protein aggregates positive for 
p62, an autophagy receptor, were detected in the brain of the nclf mouse, a naturally 
occurring model of late infantile-onset CLN6 disease, arguing for our hypothesis [12].  
In order to test the hypothesis, we here determined if anti-aggregate activity of 
pathogenic CLN6 mutants is decreased compared with that of wild-type CLN6.  
Because no physiological substrates of CLN6 have been identified at present, we 
employed four disease-causing BC mutants, identified in patients of B-
crystallinopathy presenting with different clinical symptoms, as model target proteins of 
CLN6.  Based on our data, we here propose that graded reductions in CLN6’s anti-
aggregate activity governs the clinical outcomes of CLN6 disease. 
 
2. Materials and methods 
 
2.1. Expression vectors 
 
The expression vector construction of pEGFP-N1-R120G BC mutant (R120G-EGFP), 
pcDNA4/myc- BC (WT BC) and pcDNA4/myc-CLN6 (CLN6) was described 
previously [11,13].  The DNA fragment encoding the D109H, G154S, R157H BC 
mutants were generated by recombinant PCR.  In each mutant, two fragments 
(Fragment 1 and Fragment 2) were generated by two sets of primers (Table S1) and 
WT BC.  And then, these fragments were used as templates for the second 
amplification with primers, 5’-CGGAATTCACCATGGACATCGCCATCC-3’ and 5’-
CGGTCGACCATTTCTTGGGGGCTGCG-3’.  The final PCR products were gel-
isolated, digested with BglII/PstI, and then cloned in frame into the BglII/PstI-digested 
pEGFP-N1 vector (TAKARA Bio).  To construct pcDNA4/myc-R106PfsX26 CLN6 
mutant (106fsX), performed sequential PCR used by PrimeSTAR Mutagenesis Basal 
Kit (TAKARA Bio).  The first PCR used CLN6 and primers, “316insC-Fwd” and 
“316insC-Rev” (Table S2), and the second PCR used the first PCR product and primers, 
“106fsX-Fwd” and “106fsX-Rev” (Table S2).  Then, the final product digested with 
HindIII/EcoRI and cloned in frame into the HindIII/EcoRI-digested pcDNA4/myc 
vector (Invitrogen).  Other CLN6 mutants were generated by PrimeSTAR Mutagenesis 
Basal Kit (TAKARA Bio), using two primers (Table S3) and CLN6 as a template.  All 
the constructs were subjected to DNA sequencing. 
 
2.2. Cell culture and transfection 
 
HeLa cells were grown in DMEM (WAKO, Tokyo, Japan) supplemented with 10% fetal 
bovine serum at 37 °C in a humidified cell culture incubator with 5% CO2.  For 
transfection, the cells were seeded at 1.5 × 104 cells per well onto 24-well plates 20 h 
prior to transfection.  The cells in each well were transfected with single (0.4 g) or 
two different (0.2 g each) expression vectors mixed with 1.2 l of polyethyleneimine 
(PEI) “Max” (Polysciences). 
 
2.3. Immunoblotting assays 
 
At 16 h post-transfection, HeLa cells were lysed with RIPA buffer (100 mM Tris (pH 
7.5), 150 mM NaCl, 2 mM EDTA, 1% TrironX-100, 1% DOC, 0.1% SDS and protease 
inhibitor cocktail), incubated on ice for 30 min, then centrifuged at 14,800 rpm for 10 
min.  Soluble fraction was collected, mixed with 2×Laemmli sample buffer (0.5 mM 
Tris-HCl (pH 6.8), 2.5% SDS, 25% glycerol, 2.5% 2-mercaptoethanol and 5% 
bromophenol blue), heated at 95 °C for 1 min, and subsequently performed SDS-PAGE 
and electrotransferred onto polyvinylidene difluoride membranes.  Then, the 
membranes were incubated with antibodies against Actin (1:200 diluted, Santa Cruz 
Biotechnology, C-2, sc-8432), Myc (1:200 diluted, Santa Cruz Biotechnology, 9E10, sc-
40) or GFP (1:2000 diluted, Santa Cruz Biotech, sc-9996) for 8 h at 4 ˚C.  The 
membranes were incubated for 20 min with horse radish peroxidase (HRP)-conjugated 
antibodies (1:6000 diluted, rabbit anti-mouse IgG, DAKO).  HRP on the membrane 
was detected using the ECL Advance luminescence solution (GE Healthcare Life 
Science) according to the manufacturer’s instruction. 
 
2.4. Measurement of aggregate positivity 
 
To visualize EGFP-tagged proteins, a fluorescence microscope IX-51 (Olympus, Japan) 
with 20×/0.40 NA dry objective was used.  At 16 h post-transfection, HeLa cells 
expressing EGFP-tagged BC mutants were illuminated with the mercury light (U-
LH100HGAPO).  EGFP images were captured with a digital camera WRAYCAM-
SR300 (WRAYMER, Japan) and WraySpect (WRAYMER, Japan).  WRAYCAM-
SR300 was used through 0.35×c-mount lens.  Based on the images, the percentage of 
the cells with aggregates in EGFP-positive cells was calculated.  At least 800 cells 
were analyzed for each condition in every assay. 
 
2.5. Statistical analysis 
 
All data were expressed as means ± S.E.M.  The data was accumulated under each 
condition from at least six independent experiments.  For parametric all-pairs multiple 




3.1 The inability of the R106PfsX26 CLN6 mutant to prevent aggregation of the R120G 
BC mutant 
 
The R106PfsX26 (hereafter referred to as 106fsX) human CLN6 mutant is produced by 
a 1-bp insertion (c.316insC) causing a frame shift and a premature stop codon, identical 
to that identified in the nclf mouse, a naturally occurring model of CLN6 disease [14–
17].  The detection of p62-positive aggregates in the brain of nclf mice prompted us to 
raise the possibility that CLN6's anti-aggregate activity is diminished by the 106fsX 
mutation, resulting in the accumulation of protein aggregates and in turn the 
development of CLN6 disease.  To explore this possibility, we first determined if the 
106fsX mutation indeed impairs CLN6’s anti-aggregate activity toward the R120G 
BC mutant.  Aggregation of the R120G BC mutant in HeLa cells was suppressed 
upon coexpression of Myc-tagged wild-type CLN6, as was demonstrated in our 
previous report (Fig. 1A,B).  In contrast, the anti-aggregate activity was comparable 
between the 106fsX mutant- and the insertless vector-transfected cells.  Immunoblot 
analysis revealed that the band representing the Myc-tagged 106fsX mutant was dim 
relative to that of wild-type CLN6 (Fig. 1C), consistent with the previous finding that 
this mutant undergoes rapid degradation.  Taken together, we concluded that the 
106fsX mutant is unable to repress aggregation of the R120G BC mutant due to a lack 
of anti-aggregate activity and/or relatively low expression levels, in support of our 
hypothesis that the malfunction of CLN6-driven protection system against protein 
aggregation causes CLN6 disease. 
 
3.2. Requirement of the integrity of CLN6’s third loop for its anti-aggregate activity 
 
The inability of the 106fsX mutant to antagonize the R120G BC mutant prompted us 
to probe the minimum N-terminal region of CLN6 required for its anti-aggregate 
activity.  When coexpressed in HeLa cells, the N-terminal half of CLN6 (residues 1-
162) suppressed aggregation of the R120G BC mutant to a similar extent as wild-type 
CLN6 (Fig. 2 A,B).  On the other hand, HeLa cells transfected with another CLN6 
truncated mutant (residues 1-142) or the 106fsX mutant exhibited comparably high 
aggregate positivity, indicating that a region essential for CLN6's anti-aggregate activity 
lies somewhere between amino acid positions 142 and 162.  In order to narrow down 
the responsible region, we replaced each of the amino-acid stretches 141-146, 147-151, 
152-156 and 157-161, with five alanine residues for the subsequent coexpression 
assays. (Fig. 2C; 5A1-4).  The protein level of the 5A2 mutant in transfected HeLa 
cells was extremely low as compared with that of the 5A1, 5A3, and 5A4 mutants (Fig. 
2D).  Furthermore, aggregate positivity of the 5A2 mutant-expressing cells was as high 
as that of the 106fsX mutant-expressing cells (Fig. 2E), showing that the structural 
integrity of the 147-151 amino-acid stretch is indispensable for the stability and anti-
aggregate activity of CLN6.  Considering that missense mutations at the positions 148 
and 149 have been documented in patients with CLN6 disease, we then focused on the 
middle three residues in the 147-151 stretch.  The V148A/R149A/E150A triple 
mutation severely attenuated CLN6’s anti-aggregate activity, as revealed by aggregate 
positivity of ~45% (Fig. 2C,F,G; 3A).  In contrast, the S147A/N151A double mutation 
appeared not to significantly affect the activity (Fig. 2C,F,G; 2A), demonstrating the 
148-150 amino-acid stretch is vital for CLN6 to prevent aggregation of the R120G BC 
mutant. 
 
3.3 The R149C substitution abolished CLN6's anti-aggregate activity toward the R120G 
BC mutant 
 
Situated in the middle of the 148-150 amino-acid stretch is R149, and its mutations to 
cysteine (R149C) and histidine (R149H) have been associated with CLN6 disease [18–
20].  It thus might be that these two mutations attenuate CLN6’s anti-aggregate 
activity to some extent, and that the resulting buildup of protein aggregates underlies the 
development of the disease.  To explore this possibility, we examined if the two 
substitutions affect the ability of CLN6 to antagonize aggregation of the R120G BC 
mutant.  Comparably high aggregate positivity was displayed by the R149C mutant- 
and the 106fsX mutant-transfected cells (Fig 3A,B), indicating that the R-to-C 
substitution completely abrogates CLN6’s anti-aggregate activity toward the R120G 
BC mutant.  On the other hand, the R149H mutant lowered the positivity to a similar 
degree as wild-type CLN6.  We hence concluded that the R-to-C, but not the R-to-H, 
substitution at the position 149 nullifies the ability of CLN6 to repress the R120G BC 
mutant from aggregating. 
 
3.4 The R149C mutant retained residual anti-aggregate activity 
 
The failure to block aggregation of the R120G BC mutant led us to reason that the 
R149C mutant can exert little, if any, anti-aggregate activity toward physiological 
targets of CLN6, thereby underlying the CLN6 disease pathogenesis.  It is, however, 
not feasible to explore this possibility because proteins that CLN6 acts on have been 
largely unknown.  We then assessed if the R149C mutant could antagonize other 
pathogenic BC mutants, such as D109H, G154S, and R157H, all of which have been 
reported in families diagnosed with B-crystallinopathy [21–27].  Like the R120G 
BC mutant, these BC mutants fused to EGFP aggregated to varying extents, 
consistent with a previous report [12] (Fig. 4A-C).  Unexpectedly, the R149C 
prevented aggregation of the G154S and R157H, but not of the D109H or R120G, BC 
mutants (Fig. 4D).  In contrast with the R149C mutant, the R149H mutant blocked all 
the four BC mutants from aggregating.  Together, we suggested that the R149C 
mutant is able to protect some, but not a full range, of CLN6’s physiological targets 
from aggregating, and that proteins not protected by CLN6 mediate aggregate 




We previously demonstrated that CLN6 has the ability to prevent aggregation the 
R120G BC mutant, a model aggregation-prone protein.  Based on this finding, we 
hypothesized that a buildup of protein aggregates due to a loss of CLN6's anti-aggregate 
activity results in the development of CLN6 disease, a division of NCL.  Little has 
been known about CLN6’s target proteins with the exception of CRMP2, identified as a 
CLN6 binder through yeast two-hybrid screens [28].  Consequently, we cannot even 
examine if physiological targets of CLN6 indeed aggregate to become dysfunctional 
when deprived of CLN6-mediated protection and support.  Faced with this limitation, 
we employed the four disease-causing BC mutants in order to gain insight into 
whether CLN6 is capable of countering a diverse array of aggregation-prone proteins.  
Patients with B-crystallinopathy display various combinations of cataract, myopathy 
and cardiomyopathy, depending on which BC mutant they inherit.  The disparity in 
their clinical manifestations prompted us to reason that the four pathogenic BC 
mutants differ from each other in their higher structures and accordingly help propagate 
distinct signals across the cytoplasm.  In this regard, our data indicate that CLN6 can 
antagonize at least four separate proteins destined to spontaneously aggregate. 
We showed that CLN6’s third loop plays vital roles for its anti-aggregate activity.  
Amino acids 148-150 in the loop were particularly critical as their simultaneous 
replacement with three alanine residues induced a marked drop in the activity.  These 
three residues are most likely to serve to meet conformational requirements for CLN6's 
functionality.  Among the three amino acids, the position 149 is of great interest 
because two kinds of substitutions, R149C and R149H, have been described in patients 
with adult-onset CLN6 disease, collectively termed Kufs disease.  The R149C mutant 
prevented aggregation of two out of the four pathogenic BC mutants, prompting us to 
expect that not all of CLN6’s physiological targets are protected from aggregating in 
individuals homozygous for the R149C substitution.  Likewise, individuals 
homozygous for the 106fsX mutation, affected with late infantile-onset CLN6 disease, 
would also manifest a buildup of protein aggregates given that p62-positive protein 
aggregates were detected in the nclf mouse.  It might thus be that the accumulation of 
protein aggregates entangling CLN6's targets is not just a shared feature of late 
infantile- and adult-onset CLN6 disease, but also a major cause of illness.  Of note, 
impacts on the four BC mutants showed that the R149C substitution attenuated 
CLN6's anti-aggregate activity less severely than the 106fsX mutation.  Provided that 
antagonizing effects on the four pathogenic BC mutants recapitulates what happens to 
physiological substrates of CLN6, a more diverse array of proteins could avoid 
aggregating in individuals homozygous for the R149C substitution relative to those for 
the 106fsX mutation, producing the difference in clinical symptoms between the two 
CLN6 disease subtypes.  Taken together, we propose that the extent to which CLN6’s 
anti-aggregate activity is impaired would be a key determinant of the clinical course of 
CLN6 disease: virtually complete loss of the activity due to homozygosity of the 
106fsX mutation leads to the development of late infantile-onset CLN6 disease, 
whereas the less severely impaired activity, resulting from homozygosity of the R149C 
substitution, contributes to adult-onset CLN6 disease. 
The R149H substitution was documented, combined with the P297LfsX53 (hereafter 
referred to as 297fsX) mutation in patients with adult-onset CLN6 disease.  We 
validated that the 297fsX CLN6 mutant also blocked the four pathogenic BC mutants 
from aggregating (data not shown), suggesting that the CLN6-mediated preventive 
system against protein aggregation still operates in individuals with the R149H/297fsX 
compound heterozygosity, and that their clinical manifestations are attributable to 
impairment of an as-yet-unidentified function of CLN6 irrelevant to antagonizing 
protein aggregate formation.  The success in countering the four BC mutants, 
however, does not necessarily guarantee that a full range of CLN6's targets can avoid 
aggregating in patients with compound heterozygosity of the R149H/297fsX.  The 
resulting protein aggregates and their accumulation in this setting could also be the 
primary cause of adult-onset CLN6 disease.  If this was the case, CLN6-related Kufs 
disease would be etiologically categorized into at least two subdivisions: one is 
attributable to the impairment of CLN6's anti-aggregate activity, and the other is due to 
defects in as-yet-unidentified CLN6's functions, thereby accounting for why CLN6 
disease is characterized by its heterogeneity in the age of onset and clinical course. 
Our findings suggest that CLN6 disease is caused through either of the two distinct 
mechanisms: one involves the graded reduction in CLN6's anti-aggregate activity, and 
the other does not.  We therefore propose that it is what amino acid residue replaces 
key positions of CLN6, including R149, that governs which of the pathogenic 
mechanisms predominantly operates and which subdivision of CLN6 disease develops. 
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Figure 1.  The R106PfsX26 CLN6 mutant was unable to prevent aggregate formation 
of the R120G BC mutant. 
(A) HeLa cells were cotransfected with the EGFP-tagged R120G BC mutant (R120G) 
in combination with either empty vector (Ev), wild type CLN6 (CLN6) or R106PfsX26 
CLN6 mutant (106fsX).  Images were captured at 16 hr post-transfection.  Scale bars: 
20 μm.  (B) Based on (A), the percentages of the cells with aggregates were calculated.  
The data represent mean ± SEM of ten separate experiments.  *p < 0.05.  (C) The 
whole cell lysates from (A) were immunoblotted with antibodies against Myc and Actin.  
 
Figure 2.  The 148-150 amino-acid stretch was vital for CLN6’s anti-aggregate 
activity. 
(A) Anti-aggregate activity of two truncated CLN6 mutants (1-142 and 1-162) were 
determined.  The HeLa cells were cotransfected with the R120G BC mutant (R120G) 
in combination with either wild-type CLN6, 1-162, 1-142 or 106fsX.  The data 
represent mean ± SEM of six independent experiments.  *p < 0.05.  (B) The whole 
cell lysates from (A) were immunoblotted with antibodies against Myc and Actin.  (C) 
Schematic representation of wild-type CLN6 and its mutants.  (D) The whole cell 
lysates from HeLa cells cotransfected with R120G BC mutant in combination with 
either wild-type CLN6, 5A1, 5A2, 5A3, 5A4 or 106fsX were immunoblotted with 
antibodies against Myc and Actin.  (E) The HeLa cells were cotransfected as in (D), 
and then imaged.  The percentages of the cells with aggregates were calculated as in 
Fig. 1(B).  The data represent mean ± SEM of eight independent experiments.  *p < 
0.05.  (F) The HeLa cells were cotransfected with the R120G BC mutant (R120G) in 
combination with either wild-type CLN6, 3A, 2A or 5A2.  The data represent mean ± 
SEM of seven independent experiments.  *p < 0.05.  (G) The whole cell lysates from 
(F) were immunoblotted with antibodies against Myc and Actin. 
 
Figure 3.  The R149C substitution abolished CLN6's anti-aggregate activity toward the 
R120G BC mutant. 
(A) The HeLa cells were co-transfected with the R120G BC mutant (R120G) in 
combination with either wild-type CLN6, R149C, R149H or 106fsX.  The percentages 
of the cells with aggregates were calculated as in Fig. 1(B).  The data represent mean ± 
SEM of ten independent experiments.  *p < 0.05.  (B) Whole cell lysates from (A) 
were immunoblotted with antibodies against Myc and Actin. 
 
Figure 4.  The R149C mutant retained residual anti-aggregate activity. 
(A) The cells were individually transfected with the indicated BC mutants (D109H, 
R120G, G154S, R157H).  At 16h post transfection, the cells were imaged with a 
fluorescence microscope.  Scale bars: 20 μm.  (B) Based on (A), the percentages of 
the cells with aggregates were calculated as in Fig. 1(B).  The data represent mean ± 
SEM of six independent experiments.  *p < 0.05.  (C) The whole cell lysates from the 
cells transfected with either empty vector (Ev) or EGFP-tagged BC mutants were 
immunoblotted with antibodies against GFP and Actin.  (D) The cells were 
cotransfected with the indicated combination of the EGFP-tagged BC mutants and 
Myc-tagged wild-type CLN6 and its mutants.  The percentages of the cells with 
aggregates were calculated as in Fig. 1(B).  The data represent mean ± SEM of six 









Table S1  The following primer sets are used in generating expression constructs. 
Target Sequence 
D109H Fragment 1 5’-CGGAATTCACCATGGACATCGCCATCC-3’ 
5’-GATGAAACCATGTTCGTGCTGGCGCTCTTC-3’ 
Fragment 2 5’-CAGGAACATGGTTTCATCTCCAGGGAGTTC-3’ 
5’-CGGTCGACCATTTCTTGGGGGCTGCG-3’ 
G154S Fragment 1 5’-CGGAATTCACCATGGACATCGCCATCC-3’ 
5’-GGTGCGCTCAGGGCTAGAGACCTGTTTCCT-3’ 
Fragment 2 5’-AGCCCTGAGCGCACCATTCCCATCACCCGT-3’ 
5’-CGGTCGACCATTTCTTGGGGGCTGCG-3’ 
R157H Fragment 1 5’-CGGAATTCACCATGGACATCGCCATCC-3’ 
5’-GATGGGAATGGTGTGCTCAGGGCCAGAGAC-3’ 
Fragment 2 5’-ACACCATTCCCATCACCCGTGAAGAGAAGC-3’ 
5’-CGGTCGACCATTTCTTGGGGGCTGCG-3’ 
 











Table S3  The following primers sets are used in generating the CLN6 mutants. 
Target Sequence 
1-142 5’-GGCTACTGGAATTCTGCAGATATCCAGCACAGT-3’ 
5’-AGAATTCCAGTAGCCACTGAAGAGCAGGCGGTG-3’ 
1-162 5’-ACGCTGTGGAATTCTGCAGATATCCAGCACAGT-3’ 
5’-AGAATTCCACAGCGTCTCCGGCTTGAGATTCTT-3’ 
5A1 5’-GCTGCAGCTGCTGCTTCTGTCCGTGAGAACCCC-3’ 
5’-AGCAGCAGCTGCAGCGCCACTGAAGAGCAGGCG-3’ 
5A2 5’-GCTGCAGCTGCTGCTCCCATCATCAAGAATCTC-3’ 
5’-AGCAGCAGCTGCAGCCAGGTGGTGCTGGTAGCC-3’ 
5A3 5’-GCTGCAGCTGCTGCTCTCAAGCCGGAGACGCTG-3’ 
5’-AGCAGCAGCTGCAGCGTTCTCACGGACAGACAG-3’ 
5A4 5’-GCAGCAGCAGCAGCACTGATCGACTCCTTTGAG-3’ 
5’-TGCTGCTGCTGCTGCATTCTTGATGATGGGGTT-3’ 
3A 5’-TCTGCTGCTGCTAACCCCATCATCAAG-3’ 
5’-GTTAGCAGCAGCAGACAGGTGGTGCTG-3’ 
2A 5’-CTGTCGCTGCGAACCCCATCATCAAGAA-3’ 
5’-GGTTCGCAGCGACAGACAGGTGGTGCTG-3’ 
R149C 5’-TCTGTCTGTGAGAACCCCATCATCAAG-3’ 
5’-GTTCTCACAGACAGACAGGTGGTGCTG-3’ 
R149H 5’-TCTGTCCATGAGAACCCCATCATCAAG-3’ 
5’-GTTCTCATGGACAGACAGGTGGTGCTG-3’ 
 
 
